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Abstract
Background: The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines are widely endorsed but
compliance is limited. We sought to determine whether journal-requested completion of an ARRIVE checklist improves
full compliance with the guidelines.
Methods: In a randomised controlled trial, manuscripts reporting in vivo animal research submitted to PLOS ONE
(March–June 2015) were randomly allocated to either requested completion of an ARRIVE checklist or current standard
practice. Authors, academic editors, and peer reviewers were blinded to group allocation. Trained reviewers performed
outcome adjudication in duplicate by assessing manuscripts against an operationalised version of the ARRIVE guidelines
that consists 108 items. Our primary outcome was the between-group differences in the proportion of manuscripts
meeting all ARRIVE guideline checklist subitems.
Results: We randomised 1689 manuscripts (control: n = 844, intervention: n = 845), of which 1269 were sent for peer
review and 762 (control: n = 340; intervention: n = 332) accepted for publication. No manuscript in either group
achieved full compliance with the ARRIVE checklist. Details of animal husbandry (ARRIVE subitem 9b) was the only
subitem to show improvements in reporting, with the proportion of compliant manuscripts rising from 52.1 to 74.1%
(X2 = 34.0, df = 1, p = 2.1 × 10−7) in the control and intervention groups, respectively.
Conclusions: These results suggest that altering the editorial process to include requests for a completed ARRIVE
checklist is not enough to improve compliance with the ARRIVE guidelines. Other approaches, such as more
stringent editorial policies or a targeted approach on key quality items, may promote improvements in reporting.
Keywords: ARRIVE, Reporting guidelines, Randomised controlled trial
Background
There are widespread failures across in vivo animal
research to adequately describe and report research
methods, including critical measures to reduce the risk
of experimental bias [10, 13]. Such omissions have been
shown to be associated with overestimation of effect
sizes [8, 13] and are likely to contribute, in part, to
translational failure. In an effort to improve reporting
standards, an expert working group coordinated by the
National Centre for the Replacement, Refinement and
Reduction of Animals in Research (NC3Rs) developed
the Animal Research: Reporting of In Vivo Experiments
(ARRIVE) guidelines [9], published in 2010.
Since the ARRIVE guidelines were first published, they
have been endorsed by many journals in their instruc-
tions to authors, but this has not been accompanied by
substantial improvements in reporting [2, 3, 6, 14].
Simply endorsing the guidelines does not appear to be
sufficient to encourage compliance. Recent findings
suggest that following the introduction of mandated
completion of a distinct reporting checklist at ten
Nature Journals at the stage of first revision significantly
improved the quality in reporting versus that of com-
parator journals [7, 12].
PLOS ONE is an open access online only journal
which at the time this study began published around
32,000 research articles per year. Of these, some 5000
were described in vivo animal research. At present,
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PLOS ONE instructions to authors encourage compli-
ance with the ARRIVE guidelines, but do not mandate
checklist completion. Journals have an important role
to play in ensuring that the quality of reporting in the
research they publish is robust, yet the most effective
mechanism by which they can achieve this remains
unclear.
Our aim was to assess the effect of an email request to
authors to complete an ARRIVE checklist on compliance
with the ARRIVE guidelines. The email request was at
the time of submission and requested that authors state
where in the manuscript various components of the
ARRIVE guidelines are reported.
Methods
Methodology and open data
Our protocol, data analysis plan, analysis code, data vali-
dation code, and complete dataset are available on the
Open Science Framework (https://doi.org/10.17605/OSF.
IO/XSJBV).
Ethical approval
We sought an informal ethical opinion from the BMJ
Ethics Committee, who were prepared to consider our
proposal although it was slightly out of scope. We
did this because we were unable at the time to iden-
tify an institutional ethics committee who considered
this research to fall within their remit. The majority
view of the committee was that it was ethical for
manuscripts to be randomised between different
handling methods; that it was ethical for authors,
peer reviewers, and academic editors to be kept
unaware of the existence of the study while it was in
progress; and that it was ethical for the study to
receive funding from the NC3Rs.
Randomisation of manuscripts
We developed (https://doi.org/10.5281/zenodo.1188821)
an online platform to support each stage of the project
(https://ecrf1.clinicaltrials.ed.ac.uk/iicarus/).
The PLOS ONE editorial process involves an initial
screening process, including a determination of whether
a manuscript describes animal studies, whether it
describes human studies (one manuscript might describe
both), and categorises the area of research according to
an established taxonomy. For studies reporting the use
of animals, checks are carried out to ensure that appro-
priate institutional animal care and use committee/eth-
ical approvals were in place, and authors of studies
perceived to be at high risk—for instance those animal
studies which used death as an endpoint—are contacted
to provide a valid justification. Manuscripts are then
allocated to an academic editor (AE), who assigns peer
reviewers as appropriate.
Manuscripts submitted to PLOS ONE between March
and June 2015 describing in vivo animal research were
randomised using the IICARus web platform to receive
standard editorial processing (control group) or checklist
completion requests (intervention group). The rando-
misation sequence was generated using randomisation in
the C# programming language and involved minimi-
sation (weighted at 0.75) to ensure that country of origin
(of the corresponding author) was balanced between
groups. All users of the platform were assigned a level of
access in line with their role (e.g. “Trainee”, “Reviewer”,
“Randomiser”) to ensure that any individual involved
in outcome assessment was blinded to the allocation
sequence.
On submission, authors receive an automated acknow-
ledgement from the publisher that their submission had
entered a screening phase. For manuscripts identified
during screening to include in vivo research and which
were randomised to the intervention, corresponding
authors were informed in the post screening email that a
completed ARRIVE checklist must be completed before
the manuscript could advance through the review
process. The email advised that this should include
details of the page of their manuscript on which each
ARRIVE item was addressed (an excerpt from the email
used for the intervention is available on the OSF https://
doi.org/10.17605/OSF.IO/XSJBV). If the PLOS editorial
team did not receive a checklist, it was sent back to
authors once more for completion. Manuscripts by
authors who did not complete the checklist after the
second contact, for any reason, were still passed to the
next stage and continued in the study. The contents of
completed checklists were not checked against the
manuscript for compliance at any stage.
Blinded manuscript processing
Authors, AEs, and peer reviewers were blinded to the
existence of the study. Study personnel took care, in
their public comments, not to disclose details of the
study or the journal at which the study was being con-
ducted. The journal was not named in the study proto-
col. If authors enquired as to why their manuscript was
being processed differently, they were to be advised
that these differences were due to variation within the
editorial team in the intensity with which they pursued
efforts to improve the review process.
For studies randomised to the control group, PLOS
ONE processed the manuscript according to their
normal editorial processes.
Once a final decision regarding publication was made,
the pre-publication materials for accepted manuscripts
were collated by the PLOS editorial team. Where an
ARRIVE checklist was included in the accepted materials
for publication, this was redacted, along with any reference
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in the text to the submission of a completed ARRIVE
checklist. The format of manuscripts largely excluded any
evidence that the manuscript was submitted to PLOS ONE.
If a reference to PLOS ONE was discovered in the text by
internal outcome assessors (within our research group), this
was also redacted to prevent any change in behaviour
which may result from external outcome assessors knowing
which publisher was involved in the study. Where authors
stated that the work complies with the ARRIVE guidelines
this statement was not redacted. Redacted PDFs of all
materials were provided to our research team and uploaded
to the IICARus web platform.
Outcome assessment
Primary, secondary, tertiary, and feasibility outcomes are
confirmatory and were pre-specified in our study proto-
col (https://doi.org/10.17605/OSF.IO/XSJBV). The unit
of analysis for all outcomes was the manuscript.
Our primary outcome was to assess whether the pro-
portion of publications in each group considered to fully
comply with all of the ARRIVE criteria (at the level of
the 38 subitems) was independent of group allocation.
To assess compliance with the ARRIVE guidelines in
greater detail, we assessed reporting at the subitem level.
The Landis core reporting standards [11] set out the key
aspects of study design and conduct necessary to
improve transparency of in vivo research and allow
readers to ascertain the validity of the findings reported.
We therefore wanted to assess compliance with the
ARRIVE items which form these criteria, namely, report-
ing of randomisation to experimental groups (subitem
6b), reporting of blinded outcome assessment (subitem
6b), reporting of a sample size calculation (subitem 10a),
and reporting of animal exclusions (subitem 15b). In
addition, we aimed to investigate any effects our interven-
tion may have on the process of publication by assessing
the number of manuscripts accepted for publication in
each group.
Our secondary outcomes were therefore to assess
whether:
 The proportion of publications meeting each of the
individual 38 ARRIVE subitems was independent of
group allocation (intervention/ control)
 The proportion of studies reporting all Landis
criteria subitems present in the ARRIVE guidelines
was independent of group allocation
 The proportion of submitted manuscripts accepted
for publication was independent of group allocation
We also wanted to examine whether different do-
mains, countries, or research that includes human re-
search may be associated with differences in adherence
to the ARRIVE guidelines.
For our tertiary outcomes, we assessed whether:
 The proportion of publications meeting each of the
38 ARRIVE subitems was independent of group
allocation, stratified by experimental animal
 The proportion of studies reporting all of the Landis
criteria subitems (blinded assessment of outcome,
sample size calculation, and criteria for exclusion of
experimental subjects), stratified by experimental
animal, was independent of group allocation
 The proportion of publications meeting each of the
38 ARRIVE subitems was independent of group
allocation, stratified by the country of the address of
the corresponding author
 The proportion of publications meeting each of the
38 ARRIVE subitems was independent of group
allocation, stratified by whether or not the research
also contains human data
 To examine the feasibility of implementing requests
for ARRIVE checklist completion at PLOS ONE, we
assessed outcomes relating to the duration of
processing manuscripts to gain an insight into
potential costs to the journal. We therefore assessed
the following for accepted manuscripts in each group:
 Time (days) spent in PLOS editorial office in handling
the manuscript (prior to editor assignment).
 Time (days) from manuscript submission to AE
assignment.
 Time (days) from AE assignment to first reviewer
agreed.
 Time (days) from AE assignment to first decision
 Time (days) from receipt of last review to AE decision
In addition, we assessed the following outcomes in
manuscripts that were accepted following resubmission:
 Time (days) from initial decision letter to
resubmission
 Number of cycles of resubmission
 Time (days) from resubmission to final decision
We also conducted some exploratory analyses not
defined in the study protocol. Although the majority of
authors complied with the request to complete an ARRIVE
checklist, a small number did not. By limiting our analyses
to the manuscripts that had received the intervention
(equivalent to an “on treatment” analysis), we assessed:
 The proportion of publications meeting each of the
38 ARRIVE subitems in the control and “on
treatment” intervention group
The Landis reporting criteria are minimal reporting
standards which are important to quality improvement
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efforts. Given that the reporting of randomisation to
experimental groups and blinded outcome assessment
are part of the same subitem (6b) in the ARRIVE guide-
lines, we explored each of the Landis criteria items
individually to assess:
 The proportion of publications meeting each
individual Landis criteria in each group
We divided the 20 main ARRIVE items into 38 subi-
tems. These subitems were further operationalised 108
questions (Additional file 1) which were scored by
trained outcome assessors on the web platform. Two of
these questions (0.1.0 What animal species are used in
this research? and 0.2.0: Does the manuscript include
human study?) were used only to categorise research for
analysis purposes (Tertiary outcomes) and were not
included in assessments of compliance. It was later
determined by the steering committee that six questions
from the original 108 were not strictly required to com-
ply with the ARRIVE checklist (see Additional file 1; re-
moved questions highlighted in grey) and were therefore
also excluded from the analysis. The decision to remove
data from these six questions was taken after data collec-
tion, but prior to the unblinding of group allocation.
PDF files of manuscripts were available alongside the
scoring questions. Each manuscript was scored by two
independent reviewers who were blinded to both inter-
vention status and to the score given by the alternative
reviewer. Manuscripts were presented to reviewers in
random order, and the platform did not allow the same
user to review the same manuscript twice. Discrepancies
between reviewers were reconciled by a third indepen-
dent reviewer, who could view both previous scores. For
some manuscripts, some questions were not applicable
(e.g. questions relating to fish studies in a manuscript de-
scribing rat experiments). Compliance was only assessed
against questions that were applicable to the study.
There were several deviations from the outcome
measures specified our study protocol. The time spent
in the PLOS editorial office was not disentangled from
time with the authors; therefore, it includes time for the
authors to follow any copyediting changes and requests
for documents (including the request to complete an
ARRIVE checklist). Similarly, the time spent with authors
was also included in the time from manuscript submission
to AE assignment. In addition, we had originally intended
to analyse the time in the PLOS editorial office in minutes,
but the measurement of this was not feasible. We were
unable to analyse “The proportion of submitted manu-
scripts accepted for publication, stratified by experimental
animal” (Secondary outcome measure) as we did not
receive species categorisation data for studies which were
not accepted. PLOS ONE were unable to provide us with
one of our specified feasibility measures “Time (days) for
each reviewer, from solicitation of reviews to receipt of
reviews)” and instead provided “Time (days) from AE
assignment to first decision”. “Time (days) from AE
assignment to first reviewer agreed” also differs to the out-
come described in our study protocol (“Time (days) from
AE assignment to solicitation of reviews”). In addition, we
had originally set out in our protocol that we would look
at the following feasibility outcome measures for manu-
scripts when the decision was other than “Accept” or
“Reject”: whether a revised manuscript is submitted, time
(days) from initial decision letter to resubmission, number
of cycles of resubmission, and time (days) from resubmis-
sion to final decision. However, we did not attain this
information for manuscripts which were not eventually
accepted. Therefore, all feasibility measures apply to
accepted manuscripts only.
Reviewer training
This was a challenging project, and we used crowd-
sourcing to recruit additional reviewers external to our
research group. We used our research networks and
social media to identify researchers and students across
the biomedical sciences and recruit them as outcome
assessors for the project. As an incentive, rewards were
given to external reviewers who reached a pre-specified
number of manuscript reviews or completed the most
reviews in a certain time period.
To ensure that review quality was high, we required
reviewers to complete online training prior to reviewing
manuscripts as part of the project. We developed a training
program with a pool of 10 manuscripts for which we de-
scribed “Gold standard” correct answers with explanations
and an accompanying document with further elaboration
(https://doi.org/10.17605/OSF.IO/XSJBV). To successfully
complete the training, external reviewers had to score 80%
against these gold standard answers overall and score
100% on gold standard questions relating to the Landis
criteria subitems for three consecutive training manu-
scripts. The training platform remains available (https://
ecrf1.clinicaltrials.ed.ac.uk/iicarus/) and can still be used
as a training tool for assessing manuscripts against the
ARRIVE guidelines.
Power calculations
When the study was being designed, the PLOS ONE
editorial team estimated that complete compliance with
the ARRIVE guidelines was close to zero. To have 80%
power with an alpha of 0.05, to detect an increase in full
compliance from 1 to 10% (the primary outcome) would
require 100 published manuscripts per group. To examine
each of the individual 38 ARRIVE subitems (Secondary
outcome), after correction for multiplicity of testing
(alpha = 0.0013), we would require 200 published
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manuscripts per group to detect with 80% power an
increase from 30 to 50% in the prevalence of reporting of
an individual subitem. It was estimated that at time of the
trial PLOS ONE accepted around 70% of manuscripts,
and to account for some drop out because of the use of
the same academic editor, we increased our group esti-
mate to 150 manuscripts per group for the primary out-
come, and 300 manuscripts in each group for secondary
outcomes. During the course of the study, it appeared that
acceptance rates were lower than the estimate, and so we
increased target recruitment to 1000 manuscripts, of
which we estimated 600 would be accepted for publi-
cation. Despite the risk of overpowering, we did not
curtail the study when we had reached the required
number of manuscripts accepted for publication
because we were concerned that manuscripts with short
submission to acceptance times would be enriched in the
study population and might not be representative of
all manuscripts.
Data validation
We validated the dataset, blinded to group allocation, to
minimise errors. For example, where a manuscript was
assessed as not including fish experiments, “Yes” or
“No” responses to IICARus questions only relevant to
fish species (e.g. Additional file 1, Questions 9.2.3–9.2.4)
should not have been recorded. The R code for valid-
ation, with explanations of each response validated, and
the changes we made to the data are available on the
OSF. These were uploaded prior to the unblinding of
the final results, at which point database lock occurred
and the data were not subsequently altered in any way.
Statistical analysis
All analyses were carried out using RStudio v1.0.143
with the level of statistical significance set at p < 0.05,
corrected as appropriate for multiple comparisons. Our
full statistical analysis plan and accompanying R code
was uploaded to the OSF prior to database lock.
We performed logistic regression with group allocation
and corresponding author country of origin included as
independent variables to determine any effects on full
compliance (primary outcome) and compliance with each
of the 38 subitems (secondary outcome), adjusting for the
minimised randomisation. For our primary, secondary,
and tertiary outcome measures, we used the chi-squared
test of independence to test whether compliance was in-
dependent of group membership (intervention/control).
To determine if the differences between proportions is
meaningful for each outcome measure, effect sizes were
calculated using Cohen’s H. For feasibility outcomes,
medians and interquartile ranges were calculated and the
Mann-Whitney U test was used to test whether a sig-
nificant difference existed between groups. To control
the familywise error rate of multiple comparisons, the
Holm-Bonferroni method [1] was used to adjust p values
for secondary, tertiary, and feasibility outcomes. Only
means and confidence intervals were calculated for our
exploratory analyses. A full description of our data analysis
plan is available on the OSF: https://osf.io/zgqxk/.
Statistical considerations
The proportion of compliant manuscripts was assessed
based on the number compliant manuscripts divided by
the number of applicable manuscripts. In some cases,
particularly when stratifying by manuscript country of
origin or animal species, the number of manuscripts in
each group is very low. If the number of applicable
manuscripts for any subitem (with or without stratification)
was less than 10, we did not perform statistical analysis.
The chi-squared test of Independence relies on the
assumption that no more than 20% of expected counts
are less than 5 and that no individual expected counts
are less than 1. In cases where counts were less than 5, a
Fisher’s exact test was used.
Unpaired t tests rely on a normal distribution; therefore,
if the distribution was non-normal, the Mann-Whitney U
test, a non-parametric alternative, was used and summary
medians and interquartile ranges were presented. In the
case of parametric data with unequal variance between
groups, Welch’s t test was used due to higher reliability.
Results
We randomised 1689 PLOS ONE manuscripts: 845
manuscripts to the intervention and 844 to control. Of
these, 192 were rejected by the journal and 75 manu-
scripts were withdrawn. A further 153 were excluded
due to errors, including 77 that were found not to con-
tain in vivo animal research. The reasons for these errors
are shown in Additional file 2. Of the remaining 1269
manuscripts, 672 were accepted for publication (340
control, 332 intervention) and underwent web-based
outcome assessment (Fig. 1). Manuscript allocation to
group and the corresponding number of manuscripts
from each country which were randomised and accepted
are shown in Table 1. No authors questioned the diffe-
rences in manuscript processing occurring within the
intervention group. A complete dataset detailing the
proportion compliance for each of the 108 questions is
available online (https://doi.org/10.17605/OSF.IO/XSJBV).
Quality of outcome assessment
Three hundred sixty individuals registered with the online
platform; 47 completed reviewer training, and 42 contri-
buted at least one outcome assessment. The percentage
agreement between the first and second reviewer for each
manuscript was high. For 71.6% (481/672) of manuscripts,
reviewers were in agreement on at least 80% of the
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questions. The agreement of reviewers varied consi-
derably at the level of each of the 108 individual
questions (Additional file 3: Table S1), from a kappa co-
efficient of 0.90 (0.86–0.93) for Question 1.1 (Is the species
of animal model studied reported in the title?) to a worse
than chance kappa coefficient of − 0.03 (− 0.10 - -0.04) for
Question 13.2 (Is the unit of analysis for at least one test
explicitly specified?). This distribution of kappa agreement
is displayed in a histogram (Additional file 3: Fig. S1).
Primary outcome
No manuscript achieved full compliance with the
ARRIVE checklist; therefore, there was no differ-
ence between the control and intervention groups
(X2 = 0.1, df = 1, p = 0.76). Compliance with indi-
vidual ARRIVE subitems ranged from 8 to 65%.
The median compliance was 36.8% and 39.5% of
relevant subitems in the control and intervention groups,
respectively.
Logistic regression
Country of corresponding author had no influence on
compliance either overall or for any individual subitems.
Only one subitem had improved reporting in the interven-
tion group versus control, subitem 9b (Provide details of
husbandry conditions e.g. breeding programme, light/dark
cycle, temperature, quality of water etc for fish, type of
food, access to food and water, environmental enrichment)
(increased log odds of compliance by 1.03 (p < 0.0001).
Secondary outcomes
Compliance with individual ARRIVE subitems
Only one ARRIVE subitem had significantly improved
compliance in the intervention group (Table 2). ARRIVE
Fig. 1 Manuscript processing
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subitem 9b (Provide details of husbandry conditions e.g.
breeding programme, light/dark cycle, temperature,
quality of water etc for fish, type of food, access to food
and water, environmental enrichment) was reported in
52.1% (177/340) of manuscripts in the control group
compared to 74.1% (246/332) of manuscripts in the
intervention group (X2 = 34.0, df = 1, p < 0.0001).
Reporting of animal characteristics and health status
(subitem 14) was very low, with 0.29% (1/339) and 0%
(0/332) compliance in the control and intervention
groups, respectively. Similarly, reporting of animal
housing (subitem 9a); adverse events (subitem 17b); the
order of treatment and assessment (Item 11b); impli-
cations for replacement, refinement, or reduction (subi-
tem 18c); defining primary and secondary outcomes
(subitem 12); and rationale for experimental procedures
(subitem 7d) was low, with less than 5% of manuscripts
reporting each of these items in both groups.
Figure 2 shows the percentage compliance in each
group for each ARRIVE subitem in each section of the
manuscript.
Reporting of Landis 4 subitems
Reporting of the Landis 4 criteria (blinding, randomi-
sation, animal exclusions, and use of a sample size calcu-
lation) was low and did not differ significantly between
groups (Fisher’s estimate for difference = 0.61, df = 1,
p = 0.73). 1.5% (5/340) of the control group manuscripts)
and 0.9% (3/332) of intervention group manuscripts
reported all four subitems of the Landis criteria.
Manuscript acceptance
There was no significant difference in the proportion of
accepted manuscripts between the control and intervention
Table 1 Manuscript allocation by country. Manuscripts allocated to each group per corresponding author country of origin; nR,
number randomised; nA, number accepted
Control Intervention Control Intervention
Country nR nA nR nA Country nR nA nR nA
Algeria 1 0 0 0 Malaysia 2 0 2 1
Argentina 4 1 3 1 Mexico 4 1 3 2
Australia 13 6 13 11 Netherlands 9 6 13 12
Austria 6 3 1 1 North Korea 5 4 0 0
Belgium 3 3 4 4 New Zealand 0 0 1 1
Brazil 29 13 33 13 Norway 3 3 0 0
Canada 15 12 16 12 Pakistan 0 0 1 0
Chile 1 1 4 2 Poland 2 2 5 3
China 135 38 157 54 Portugal 2 1 6 3
Colombia 1 1 0 0 Puerto Rico 0 0 1 0
Czech Republic 1 1 1 0 Romania 1 1 1 0
Denmark 6 3 8 3 Russia 3 2 1 1
Egypt 2 1 6 4 Saudi Arabia 3 2 1 0
Finland 1 0 1 1 Singapore 3 1 7 2
France 10 6 15 13 Slovakia 1 0 0 0
French Guiana 1 0 0 0 South Africa 1 1 2 0
Germany 34 24 29 13 South Korea 28 14 26 8
Greece 2 2 0 0 Spain 15 8 11 7
Hong Kong 1 0 3 2 Sweden 10 7 11 6
Hungary 1 0 0 0 Switzerland 6 5 7 5
India 15 8 10 3 Taiwan 19 13 8 3
Iran 1 1 1 1 Thailand 0 0 1 0
Ireland 2 2 1 1 Turkey 2 0 1 0
Israel 1 1 2 2 Ukraine 0 0 1 0
Italy 8 6 15 11 United Kingdom 17 10 18 9
Japan 47 27 46 23 United States 143 97 150 94
Kuwait 2 2 0 0
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Table 2 Percentage compliance for each ARRIVE subitem; %, percentage of compliant manuscripts; CI, confidence interval; n,
number of compliant manuscripts; N, total number of applicable manuscripts; Adj p, adjusted p value; Cohen’s H, Cohen’s H effect
size
Control Intervention
ARRIVE subitem % 95% CIs n N % 95% CIs n N Adj. p Cohen’s H
1 41.76 36.5–47.2 142 340 44.58 39.2–50.1 148 332 > 0.99 0.06
2 71.76 66.6–76.4 244 340 67.47 62.1–72.4 224 332 > 0.99 −0.09
3a 100.00 98.6–100 340 340 100.00 98.6–100 332 332 > 0.99 0.00
3b 34.12 29.1–39.5 116 340 36.14 31–41.6 120 332 > 0.99 0.04
4 91.18 87.5–93.9 310 340 93.07 89.6–95.5 309 332 > 0.99 0.07
5 69.41 64.2–74.2 236 340 72.59 67.4–77.3 241 332 > 0.99 0.07
6a 70.00 64.8–74.8 238 340 75.00 69.9–79.5 249 332 > 0.99 0.11
6b 8.33 5.7–12 28 336 10.49 7.5–14.5 34 324 > 0.99 0.07
6c 90.00 86.2–92.9 306 340 88.86 84.8–91.9 295 332 > 0.99 −0.04
7a 16.76 13–21.3 57 340 16.87 13.1–21.4 56 332 > 0.99 0.00
7b 44.37 38.7–50.2 134 302 51.33 45.5–57.1 154 300 > 0.99 0.14
7c 8.64 5.8–12.5 26 301 14.09 10.5–18.7 42 298 > 0.99 0.17
7d 3.63 1.9–6.6 11 303 3.63 1.9–6.6 11 303 > 0.99 0.00
8a 4.71 2.8–7.7 16 340 7.83 5.3–11.4 26 332 > 0.99 0.13
8b 57.06 51.6–62.4 194 340 62.65 57.2–67.8 208 332 > 0.99 0.11
9a 0.30 0–1.9 1 337 2.74 1.3–5.3 9 328 0.39 0.22
9b 52.06 46.6–57.5 177 340 74.10 69–78.7 246 332 < 0.001 0.46
9c 14.71 11.2–19 50 340 20.48 16.4–25.3 68 332 > 0.99 0.15
10a 37.35 32.2–42.8 127 340 43.67 38.3–49.2 145 332 > 0.99 0.13
10b 3.53 1.9–6.2 12 340 7.53 5–11.1 25 332 > 0.99 0.18
10c 18.15 14.3–22.8 61 336 14.64 11.1–19.1 47 321 > 0.99 −0.10
11a 4.82 2.8–8 15 311 7.49 4.9–11.2 23 307 > 0.99 0.11
11b 1.24 0.4–3.4 4 323 2.88 1.4–5.6 9 313 > 0.99 0.12
12 1.76 0.7–4 6 340 3.01 1.5–5.6 10 332 > 0.99 0.08
13a 87.50 83.4–90.7 294 336 89.91 86–92.9 294 327 > 0.99 0.08
13b 44.08 38.7–49.6 149 338 44.51 39.1–50.1 146 328 > 0.99 0.01
13c 10.06 7.2–13.9 34 338 12.80 9.5–17 42 328 > 0.99 0.09
14 0.29 0–1.9 1 340 0.00 0–1.4 0 332 > 0.99 −0.11
15a 37.35 32.2–42.8 127 340 37.35 32.2–42.8 124 332 > 0.99 0.00
15b 12.65 9.4–16.8 43 340 14.46 10.9–18.8 48 332 > 0.99 0.05
16 78.55 73.7–82.8 260 331 80.94 76.1–85 259 320 > 0.99 0.06
17a 16.47 12.8–20.9 56 340 21.69 17.5–26.6 72 332 > 0.99 0.13
17b 1.18 0.4–3.2 4 340 1.81 0.7–4.1 6 332 > 0.99 0.05
18a 100.00 98.6–100 340 340 99.40 97.6–99.9 330 332 > 0.99 −0.16
18b 26.47 21.9–31.6 90 340 28.31 23.6–33.5 94 332 > 0.99 0.04
18c 2.94 1.5–5.5 10 340 3.01 1.5–5.6 10 332 > 0.99 0.00
19 77.94 73.1–82.2 265 340 77.71 72.8–82 258 332 > 0.99 −0.01
20 51.47 46–56.9 175 340 52.71 47.2–58.2 175 332 > 0.99 0.02
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groups, being 54.7% (340/622) and 51.3% (322/647)
respectively. (X2 = 1.30, df = 1, p = 0.25).
Tertiary outcomes
Compliance by animal species
We removed animal species from the analysis where fewer
than ten manuscripts reported the use of a species for
control and intervention groups, leaving only rat and
mouse studies. In studies involving mice, only reporting of
ARRIVE subitem, 9b (Provide details of husbandry
conditions e.g. breeding programme, light/dark cycle,
temperature, quality of water etc for fish, type of food,
access to food and water, environmental enrichment)
increased significantly from 49.5% (105/211) in the control
group to 70.2% (135/192) in the intervention group
(X2 = 16.8, df = 1, p = 0.003). No subitem had a statistically
significant difference between groups in rat studies.
Results are summarised in Tables 3 and 4. There was no
difference in Landis 4 compliance between animal species.
Feasibility measures
Re-assignment of academic editors occurred in a small
number of cases (7/672), which confounds the recorded
time in each stage and prevented us from analysing the
feasibility outcomes for these manuscripts. The time
from receipt of last review to final AE decision was
missing from a large proportion of the remaining manu-
scripts (342/665), and so this analysis was not per-
formed. Ten additional manuscripts were also excluded
from the feasibility dataset due to missing data on one
or more feasibility outcome s. After these exclusions, the
feasibility analysis was performed on 328/340 manu-
scripts in the control group and 327/332 in the inter-
vention group. For analysis of resubmitted articles, seven
manuscripts were removed as these were accepted at
first decision leaving 323/340 in the control group and
325/332 in the intervention group.
Upon examining histograms for each variable and
calculating skew using the skew() function, all data for
these outcomes were found to be right skewed, so we
used Mann-Whitney U test to compare timings between
groups. Time spent in the PLOS editorial office was
significantly higher (p < 0.0001) for manuscripts in the
intervention group with a median of 9 days (interquartile
range [IQR] = 6–16.5) compared to the control group
with a median of 6 days [3–10]. Time from submission to
Fig. 2 Percentage compliance for each ARRIVE subitem; percentage compliance for each ARRIVE subitem with 95% confidence intervals; asterisk
denotes statistical significance; figure divided into article sections specified in the ARRIVE guidelines
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Table 3 ARRIVE subitem compliance in mouse studies. %, percentage of compliant manuscripts; CI, confidence interval; n, number
of compliant manuscripts; N, total number of applicable manuscripts; Adj p, adjusted p value; Cohen’s H, Cohen’s H effect size
Control Intervention
ARRIVE subitem % 95% CIs n N % 95% CIs n N Adj p Cohen’s H
1 37.44 31–44.4 79 211 37.50 30.7–44.8 72 192 > 0.99 0.00
2 68.25 61.4–74.4 144 211 60.42 53.1–67.3 116 192 > 0.99 − 0.16
3a 100.00 97.8–100 211 211 100.00 97.6–100 192 192 > 0.99 0.00
3b 30.33 24.3–37.1 64 211 29.69 23.4–36.8 57 192 > 0.99 − 0.01
4 89.10 83.9–92.8 188 211 92.19 87.2–95.4 177 192 > 0.99 0.11
5 67.77 61–73.9 143 211 71.88 64.9–78 138 192 > 0.99 0.09
6a 63.98 57.1–70.4 135 211 71.35 64.3–77.5 137 192 > 0.99 0.16
6b 5.24 2.8–9.4 11 210 7.89 4.6–12.9 15 190 > 0.99 0.11
6c 90.05 85–93.6 190 211 91.15 86–94.6 175 192 > 0.99 0.04
7a 17.54 12.8–23.5 37 211 17.71 12.7–24 34 192 > 0.99 0.00
7b 44.68 37.5–52.1 84 188 48.57 41–56.2 85 175 > 0.99 0.08
7c 6.91 3.9–11.8 13 188 9.83 6–15.5 17 173 > 0.99 0.11
7d 3.16 1.3–7.1 6 190 2.27 0.7–6.1 4 176 > 0.99 − 0.05
8a 4.74 2.4–8.8 10 211 6.25 3.4–10.9 12 192 > 0.99 0.07
8b 55.45 48.5–62.2 117 211 60.94 53.6–67.8 117 192 > 0.99 0.11
9a 0.47 0–3 1 211 2.08 0.7–5.6 4 192 > 0.99 0.15
9b 49.76 42.8–56.7 105 211 70.31 63.2–76.6 135 192 0.003 0.42
9c 15.17 10.7–20.9 32 211 23.96 18.2–30.7 46 192 > 0.99 0.22
10a 27.01 21.3–33.6 57 211 31.25 24.9–38.4 60 192 > 0.99 0.09
10b 2.84 1.2–6.4 6 211 5.73 3–10.3 11 192 > 0.99 0.14
10c 21.15 15.9–27.5 44 208 15.43 10.7–21.6 29 188 > 0.99 − 0.15
11a 4.12 1.9–8.3 8 194 5.00 2.5–9.6 9 180 > 0.99 0.04
11b 1.93 0.6–5.2 4 207 0.54 0–3.4 1 185 > 0.99 −0.13
12 0.00 0–2.2 0 211 3.65 1.6–7.7 7 192 0.40 0.38
13a 87.20 81.8–91.3 184 211 89.58 84.2–93.4 172 192 > 0.99 0.07
13b 46.92 40.1–53.9 99 211 42.71 35.7–50 82 192 > 0.99 − 0.08
13c 8.06 4.9–12.8 17 211 11.46 7.5–17 22 192 > 0.99 0.12
14 0.00 0–2.2 0 211 0.00 0–2.4 0 192 > 0.99 0.00
15a 36.02 29.6–42.9 76 211 36.46 29.7–43.7 70 192 > 0.99 0.01
15b 11.37 7.6–16.6 24 211 10.94 7.1–16.4 21 192 > 0.99 − 0.01
16 84.62 78.8–89.1 176 208 80.95 74.5–86.1 153 189 > 0.99 − 0.10
17a 15.64 11.2–21.4 33 211 23.44 17.8–30.2 45 192 > 0.99 0.20
17b 0.95 0.2–3.7 2 211 2.60 1–6.3 5 192 > 0.99 0.13
18a 100.00 97.8–100 211 211 98.96 95.9–99.8 190 192 > 0.99 − 0.20
18b 27.01 21.3–33.6 57 211 26.56 20.6–33.5 51 192 > 0.99 − 0.01
18c 3.32 1.5–7 7 211 3.13 1.3–7 6 192 > 0.99 − 0.01
19 82.46 76.5–87.2 174 211 81.77 75.4–86.8 157 192 > 0.99 − 0.02
20 51.18 44.2–58.1 108 211 56.25 48.9–63.3 108 192 > 0.99 0.10
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Table 4 ARRIVE subitem compliance in rat studies. %, percentage of compliant manuscripts; CI, confidence interval; n, number of
compliant manuscripts; N, total number of applicable manuscripts; Adj p, adjusted p value; Cohen’s H, Cohen’s H effect size
Control Intervention
ARRIVE subitem % 95% CIs n N % 95% CIs n N Adj p Cohen’s H
1 47.27 33.9–61.1 26 55 59.09 46.3–70.8 39 66 > 0.99 0.24
2 83.64 70.7–91.8 46 55 81.82 70–89.9 54 66 > 0.99 − 0.05
3a 100.00 91.9–100 55 55 100.00 93.1–100 66 66 > 0.99 0.00
3b 20.00 10.9–33.4 11 55 34.85 23.8–47.7 23 66 > 0.99 0.34
4 96.36 86.4–99.4 53 55 96.97 88.5–99.5 64 66 > 0.99 0.03
5 83.64 70.7–91.8 46 55 80.30 68.3–88.7 53 66 > 0.99 − 0.09
6a 90.91 79.3–96.6 50 55 87.88 77–94.3 58 66 > 0.99 − 0.10
6b 24.53 14.2–38.6 13 53 21.54 12.7–33.8 14 65 > 0.99 − 0.07
6c 98.18 89–99.9 54 55 89.39 78.8–95.3 59 66 > 0.99 − 0.39
7a 9.09 3.4–20.7 5 55 12.12 5.7–23 8 66 > 0.99 0.10
7b 44.44 31.2–58.5 24 54 60.32 47.2–72.2 38 63 > 0.99 0.32
7c 5.56 1.4–16.3 3 54 14.29 7.1–25.9 9 63 > 0.99 0.30
7d 1.85 0.1–11.2 1 54 6.35 2.1–16.3 4 63 > 0.99 0.24
8a 1.82 0.1–11 1 55 10.61 4.7–21.2 7 66 > 0.99 0.39
8b 63.64 49.5–75.9 35 55 75.76 63.4–85.1 50 66 > 0.99 0.26
9a 0.00 0–8.1 0 55 6.15 2–15.8 4 65 > 0.99 0.50
9b 69.09 55–80.5 38 55 90.91 80.6–96.3 60 66 0.37 0.57
9c 12.73 5.7–25.1 7 55 13.64 6.8–24.8 9 66 > 0.99 0.03
10a 52.73 38.9–66.1 29 55 60.61 47.8–72.2 40 66 > 0.99 0.16
10b 1.82 0.1–11 1 55 12.12 5.7–23 8 66 > 0.99 0.44
10c 5.45 1.4–16.1 3 55 3.17 0.6–12 2 63 > 0.99 − 0.11
11a 3.77 0.7–14.1 2 53 10.77 4.8–21.5 7 65 > 0.99 0.28
11b 0.00 0–8.4 0 53 4.69 1.2–14 3 64 > 0.99 0.44
12 1.82 0.1–11 1 55 1.52 0.1–9.3 1 66 > 0.99 − 0.02
13a 94.55 83.9–98.6 52 55 90.77 80.3–96.2 59 65 > 0.99 − 0.15
13b 41.82 28.9–55.9 23 55 48.48 36.1–61 32 66 > 0.99 0.13
13c 18.18 9.5–31.4 10 55 16.67 9–28.3 11 66 > 0.99 − 0.04
14 0.00 0–8.1 0 55 0.00 0–6.9 0 66 > 0.99 0.00
15a 43.64 30.6–57.6 24 55 43.94 31.9–56.7 29 66 > 0.99 0.01
15b 12.73 5.7–25.1 7 55 16.67 9–28.3 11 66 > 0.99 0.11
16 70.37 56.2–81.6 38 54 87.30 76–94 55 63 > 0.99 0.42
17a 12.73 5.7–25.1 7 55 12.12 5.7–23 8 66 > 0.99 − 0.02
17b 1.82 0.1–11 1 55 0.00 0–6.9 0 66 > 0.99 − 0.27
18a 100.00 91.9–100 55 55 100.00 93.1–100 66 66 > 0.99 0.00
18b 18.18 9.5–31.4 10 55 28.79 18.6–41.4 19 66 > 0.99 0.25
18c 3.64 0.6–13.6 2 55 1.52 0.1–9.3 1 66 > 0.99 − 0.14
19 74.55 60.7–84.9 41 55 86.36 75.2–93.2 57 66 > 0.99 0.30
20 43.64 30.6–57.6 24 55 39.39 27.8–52.2 26 66 > 0.99 − 0.09
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academic editor assignment was also significantly higher
in the intervention group (13 days, range 9–22) than in
the control group (9 days, range 7–14) (p < 0.0001). No
statistically significant differences were identified for
other feasibility outcomes (Table 5).
Compliance by country
There were no statistically significant differences in com-
pliance between control and intervention groups across
any corresponding author country of origin. Although we
did not set out to compare differences in compliance with
different ARRIVE subitems across countries, we present
these data in Fig. 3.
Human studies compliance
In manuscripts without human subjects, reporting of
one ARRIVE subitem, 9b (Provide details of husbandry
conditions e.g. breeding programme, light/dark cycle,
temperature, quality of water etc for fish, type of food,
access to food and water, environmental enrichment)
increased significantly from 52.4% (172/316) in the con-
trol group to 76.9% (227/295) in the intervention group
(X2 = 33.2, df = 1, p < 0.0001). In manuscripts containing
human subjects, compliance also rose from 20.8% (5/24)
to 51.35% (19/37) in the intervention group for this
subitem, although we were limited by small sample
sizes and this change was not found to be statistically
significant (X2 = 4.47, df = 1, p = 1).
Exploratory outcomes
Compliance in true intervention group
Despite allocation to the intervention group, a small
subset (n = 31/332) of authors did not comply with the
request to submit a completed checklist, and therefore,
31 manuscripts were in the intervention group without a
completed ARRIVE checklist. We sought to determine
compliance with each of the 38 subitems in the “true”
intervention group (those submitted with a completed
checklist), compared to the control group. The pattern
of compliance is similar to that of the full intervention
group compared to controls, suggesting that these
instances of non-compliance did not impact on
results. Summary statistics are presented in Table 6.
Landis item individual compliance
To determine if there had been any changes in individual
Landis subitems, we investigated randomisation, blinding,
reporting of a sample size calculation, and reporting of
exclusions separately (Fig. 4). Although we did not analyse
these comparisons using inferential statistics, there
appears to be some improvements in reporting of ran-
domisation and sample size calculations. 29.1% (91/313)
of manuscripts in the control group reported whether or
not random assignment occurred, compared to 41.5%
(125/301) in the intervention group (Cohen’s H effect
size = 0.26), while 3.5% (12/40) of control manuscripts
reported sample size calculations compared to 7.6%
(25/330) in the intervention group (Cohen’s H effect
size = 0.18). For the reporting of animal exclusions, 12.6%
(43/340) of manuscripts complied in the control group
versus 14.5% (48/332) in the intervention group (Cohen’s
H effect size = 0.05). Finally, 18.8% (63/334) and 19.2%
(62/323) of manuscripts reported blinded outcome assess-
ment in the control and intervention groups, respectively
(Cohen’s H effect size = 0.01).
Discussion
Requesting completion of an ARRIVE checklist at
submission did not increase full adherence with the
ARRIVE guidelines. Compliance with the operationalised
ARRIVE checklist was poor overall, with no manuscripts
in either group even approaching full compliance; the
median compliance was less than 40%, equivalent to
around 15 of 38 subitems; and the intervention only
increased compliance with one subitem, reporting of
animal husbandry conditions. There is considerable
room for improvement, and this study shows that an
editorial policy of making ARRIVE checklist completion
“mandatory” without compliance checks has little or
no impact.
Table 5 Feasibility measures; Q1–Q3, interquartile range; N, number of applicable manuscripts; Adj p, adjusted p value; n.s, not
significant
Feasibility outcomes Control Intervention
Median Q1–Q3 N Median Q1–Q3 N Adj p
Days in PLOS editorial office 6 3–10 328 9 6–16.5 327 < 0.0001
Days from submission to AE assignment 9 7–14 328 13 9–22 327 < 0.0001
Days from AE assignment to reviewer assignment 3 1–8 328 3 1–9 327 > 0.99
Days from AE assignment first decision 28 20–41.3 328 27 19–41 327 > 0.99
Days from initial decision to resubmission 41 23.5–51.5 323 40 23–45 325 > 0.99
Cycles of resubmission 1 1–2 323 1 1–2 325 > 0.99
Days from resubmission to final decision 31 15.5–58 323 34 16–59 325 > 0.99
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There were some noticeable differences between the
control and intervention group for some subitems e.g.
the proportion of manuscripts compliant with 10b (Ex-
plain how the number of animals was arrived at. Provide
details of any sample size calculation used) was double
the size in the intervention group compared to control
(3.53% vs 7.53%; Cohen’s H effect size = 0.18). However,
our power calculation determined that a meaningful
effect would be substantially larger to justify the increased
burden for authors associated with implementation by
PLOS ONE.
It may be that simply requesting that authors complete
checklist, without any additional editorial checks to
determine whether the checklist is truly indicative of
compliance, may not be enough to improve adherence
to the ARRIVE guidelines. Adherence to the reporting
guidelines within in the clinical literature such as
CONSORT and STROBE have been widely assessed and
may inform interventions to improve compliance with
preclinical guidelines. Journal endorsement of these
guidelines appear to have improved reporting quality
[15, 18]; however, it is often unclear what actions journals
take to promote adherence [17] and the extent of editorial
involvement is likely to have an impact. Prior reports indi-
cate that assessing compliance with reporting guidelines
at the stage of peer review leads to a significant improve-
ment of reporting quality [5]. Other approaches (e.g.
actions on the part of funders or institutions) may
also be beneficial, but a successful strategy is likely to
be multi-dimensional. Further, the findings reported here
and the limited agreement between outcome assessors
both in this study and in the recent investigation of study
quality following the introduction of a new editorial policy
at Nature journals [12] suggests that an important part of
guideline development should be refinement of the
content, the number of items (with fewer generally being
better), and the agreement between assessors. It may be
that a more formal adoption of research improvement
strategies, with an original focus on a smaller number of
items judged by a stakeholder to be of greatest impor-
tance, will allow an incremental approach to enabling and
measuring improvement.
Our findings are in line with prior reports that en-
dorsement by editors and reviewers has not signi-
ficantly improved reporting of ARRIVE quality items
[3, 6]. We need therefore a better understanding of
the barriers to implementing quality checklists for
animal experiments. It has been suggested that
requesting checklist adherence at the submission stage
may be too late, given the observed correlation between
reporting at the planning application stage and at the
publication stage [19]. The PREPARE (Planning Research
and Experimental Procedures on Animals: Recommen-
dations for Excellence) guidelines [16] were published
recently and may be a useful tool, in combination
with the ARRIVE checklist, to promote a greater
focus on experimental rigour at all stages of the
research cycle.
Fig. 3 Compliance by country; percentage compliance for each ARRIVE subitem for manuscripts in each country (for countries with N
manuscripts ≥10)
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Our results contrast with recent reports of improve-
ment in quality following mandated checklist completion
following a change in editorial policy at Nature journals
[7, 12]. However, in both reports, study quality was
retrospectively assessed in publications published prior
to and after the introduction of the Nature quality
checklist, which was established in 2015 as part of an
organisation wide approach with substantial editorial
involvement. In contrast, the current trial investigated
an intervention targeted at selected manuscripts, with-
out further editorial involvement.
Perhaps unsurprisingly, due to the additional time
required for ARRIVE checklist requests, both the number
of days manuscripts spent in the PLOS editorial office and
Table 6 True intervention ARRIVE subitem compliance; %, percentage of compliant manuscripts; CI, confidence interval; n, number
of compliant manuscripts; N, total number of applicable manuscripts
Control Intervention
ARRIVE subitem % 95% CIs n N % 95% CIs n N
1 41.76 36.5–47.2 142 340 45.85 40.1–51.7 138 301
2 71.76 66.6–76.4 244 340 66.45 60.8–71.7 200 301
3a 100.00 98.6–100 340 340 100.00 98.4–100 301 301
3b 34.12 29.1–39.5 116 340 35.88 30.5–41.6 108 301
4 91.18 87.5–93.9 310 340 93.02 89.4–95.5 280 301
5 69.41 64.2–74.2 236 340 72.43 66.9–77.3 218 301
6a 70.00 64.8–74.8 238 340 75.42 70.1–80.1 227 301
6b 8.33 5.7–12 28 336 9.49 6.5–13.6 28 295
6c 90.00 86.2–92.9 306 340 88.70 84.4–91.9 267 301
7a 16.76 13–21.3 57 340 16.94 13–21.8 51 301
7b 44.37 38.7–50.2 134 302 52.21 46.1–58.3 142 272
7c 8.64 5.8–12.5 26 301 14.07 10.3–18.9 38 270
7d 3.63 1.9–6.6 11 303 4.00 2.1–7.2 11 275
8a 4.71 2.8–7.7 16 340 7.97 5.3–11.8 24 301
8b 57.06 51.6–62.4 194 340 62.46 56.7–67.9 188 301
9a 0.30 0–1.9 1 337 3.03 1.5–5.9 9 297
9b 52.06 46.6–57.5 177 340 74.75 69.4–79.5 225 301
9c 14.71 11.2–19 50 340 21.26 16.9–26.4 64 301
10a 37.35 32.2–42.8 127 340 43.19 37.6–49 130 301
10b 3.53 1.9–6.2 12 340 7.64 5–11.4 23 301
10c 18.15 14.3–22.8 61 336 15.12 11.3–19.9 44 291
11a 4.82 2.8–8 15 311 7.53 4.8–11.4 21 279
11b 1.24 0.4–3.4 4 323 3.17 1.6–6.1 9 284
12 1.76 0.7–4 6 340 2.99 1.5–5.8 9 301
13a 87.50 83.4–90.7 294 336 89.90 85.8–93 267 297
13b 44.08 38.7–49.6 149 338 45.97 40.2–51.8 137 298
13c 10.06 7.2–13.9 34 338 12.75 9.3–17.2 38 298
14 0.29 0–1.9 1 340 0.00 0–1.6 0 301
15a 37.35 32.2–42.8 127 340 36.54 31.1–42.3 110 301
15b 12.65 9.4–16.8 43 340 14.95 11.2–19.6 45 301
16 78.55 73.7–82.8 260 331 81.03 75.9–85.3 235 290
17a 16.47 12.8–20.9 56 340 21.93 17.5–27.1 66 301
17b 1.18 0.4–3.2 4 340 1.66 0.6–4.1 5 301
18a 100.00 98.6–100 340 340 99.34 97.4–99.9 299 301
18b 26.47 21.9–31.6 90 340 27.57 22.7–33.1 83 301
18c 2.94 1.5–5.5 10 340 2.99 1.5–5.8 9 301
19 77.94 73.1–82.2 265 340 78.07 72.9–82.5 235 301
20 51.47 46–56.9 175 340 54.49 48.7–60.2 164 301
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the number of days from manuscript submission to AE
assignment were found to be significantly longer in the
intervention group. The editorial resource required to
ensure that all accepted publications meet the require-
ments of the ARRIVE checklist is likely to be considerable,
given that PLOS ONE is a high-volume publisher, with
around 44,000 submissions per year. The most feasible
and effective way to encourage compliance to the ARRIVE
guidelines, or indeed any reporting guideline, remains to
be determined, but an ongoing review of interventions to
improve adherence to reporting guidelines may shed some
light on this issue and direct future investigations [4].
Another consideration is the perceived clarity of the
checklist to authors and reviewers. Although reviewer
agreement was generally high, a few questions were less
well understood by our outcome assessors which suggests
the current guidelines may require clearer dissemination
among the research community.
Limitations
Due to modest sample sizes, we were unable to inves-
tigate whether the intervention was more successful in
countries with high awareness and adoption of the
ARRIVE guidelines such as the UK, where the ARRIVE
guidelines were developed and where many institutions
have endorsed them. Furthermore, we did not perform a
power calculation for outcomes beyond our primary and
main secondary outcomes and it is possible that this,
coupled with stringent adjustments for multiplicity of
testing in some instances, may have prevented us from
detecting any significant differences.
Furthermore, our intervention only involved requests for
authors to complete an ARRIVE checklist. PLOS ONE did
not fully mandate checklist completion, as manuscripts
without a checklist were still allowed to proceed through
the trial. Furthermore, PLOS ONE did not evaluate the
accuracy of the completed checklists against each manu-
script. It is possible that further emphasis on evaluation
and checklist adherence may result in an enhancement of
study quality.
Our interpretation of compliance was also influenced
by our operationalisation of the ARRIVE checklist used
for outcome assessment. It was often difficult to deter-
mine how many of the details provided in the ARRIVE
guidelines were sufficient for full compliance to that
ARRIVE subitem.
There were unforeseen difficulties in attaining data for
some outcomes, which meant that we could not assess
all outcomes presented in our study protocol. This was
most apparent for feasibility outcomes, where there were
substantial deviations from our protocol. Furthermore,
the project was subject to research waste due to over-
powering our primary and secondary outcome measures.
As manuscripts submitted to PLOS ONE as part of the
study were treated differently, the existence of the study
could have leaked to external sources; however, to the
best of our knowledge, this was not the case.
Since the ARRIVE guidelines were developed by the
NC3Rs, no individual employed by the NC3Rs was
permitted to conduct any outcome assessment on the
IICARus platform.
Conclusions
Research must be described in sufficient detail to allow
research users critically to appraise experimental design,
to allow them to assess the validity of the findings pre-
sented. Replication studies require, for their design, full
details of what was done. Transparency in the reporting
of research is paramount. Manuscripts must therefore
be described in enough detail for readers to understand
Fig. 4 Landis 4 individual compliance; percentage compliance for each Landis criteria present in the ARRIVE guidelines with 95% confidence intervals
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the research methodology and make informed judge-
ment of quality and risk of bias. At present, reporting
quality is, on average, disappointingly poor. However,
our findings show that simply requesting that re-
searchers improve reporting is not effective. Editorial
checks of compliance and further measures to mandate
checklist completion may be required to see improve-
ments in quality.
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